Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | COVID-19 in HCT recipients

Akshay Sharma • 2 Feb 2021
TCT 2021
General

Akshay Sharma, MBBS, St. Jude Children’s Research Hospital, Memphis, TN, discusses the results of a study evaluating the outcomes of patients who have undergone hematopoietic cell transplantation (HCT) who were diagnosed with COVID-19. In this evaluation, it was found that among recipients of allogeneic HCT with COVID-19, older age, male gender, and development of COVID-19 within 12 months of transplant were risk factors for increased mortality. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Akshay Sharma

1:45
Impact of cytogenetic abnormalities on OS following SCT in pediatric AML
Akshay Sharma • 12 Dec 2022
1:44
Phase II study of MGTA-145 in combination with plerixafor for HSC mobilization in patients with SCD
Akshay Sharma • 12 Dec 2022
0:56
Treatment of severe SCD with OTQ923 CRISPR/Cas9 gene therapy
Akshay Sharma • 12 Dec 2022
2:43
A machine learning model to improve outcome prediction following allogeneic transplantation
Akshay Sharma • 12 Dec 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals